A novel approach to identify driver genes involved in androgen-independent prostate cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Schinke, Ellyn N ^a   Bii, Victor ^a   Nalla, Arun ^a   Rae, Dustin T ^a   Tedrick, Laura ^a   Meadows, Gary G ^a   Trobridge, Grant D ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Center for Reproductive Biology   (United States)

Author keywords

Androgen independent prostate cancer; Lentiviral vector; Mutagenesis screen; Prostate cancer; Proto oncogene; Shuttle vector

Indexed keywords

ANDROGEN; ATP SYNTHASE MITOCHONDRIAL F1 COMPLEX ASSEMBLY FACTOR 1; GRINL1A COMPLEX LOCUS 1 PROTEIN; LENTIVIRUS VECTOR; MEX 3 RNA BINDING FAMILY MEMBER D PROTEIN; POLYMERASE I AND TRANSCRIPT RELEASE FACTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; ATPAF1 PROTEIN, HUMAN; CHAPERONE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PTRF PROTEIN, HUMAN; RNA BINDING PROTEIN; SMALL INTERFERING RNA;

ANDROGEN DEFICIENCY; ANDROGEN INDEPENDENT PROSTATE CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SUSCEPTIBILITY; CHROMOSOME; CONTROLLED STUDY; ESCHERICHIA COLI; GENE IDENTIFICATION; GENE LOCUS; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERMINAL REPEAT; MALE; MOUSE; MUTAGENESIS; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROVIRUS; RNA INTERFERENCE; SHUTTLE VECTOR; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CLONE; CELL PROLIFERATION; DEFICIENCY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HIGH THROUGHPUT SCREENING; LENTIVIRINAE; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CLONE CELLS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; GENETIC VECTORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LENTIVIRUS; MALE; MICE; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; MOLECULAR CHAPERONES; MUTAGENESIS, INSERTIONAL; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TERMINAL REPEAT SEQUENCES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901944726     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-120     Document Type: Article

References (67)

1. Uren AG, Kool J, Berns A, van Lohuizen M. Retroviral insertional mutagenesis: past, present and future. Oncogene 2005, 24:7656-7672. 10.1038/sj.onc.1209043, 16299527.
2. Trobridge GD. Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther 2011, 11:581-593. 10.1517/14712598.2011.562496, 3443588, 21375467.
3. Landrette SF, Xu T. Somatic genetics empowers the mouse for modeling and interrogating developmental and disease processes. PLoS Genet 2011, 7:e1002110. 10.1371/journal.pgen.1002110, 3140981, 21814514.
4. Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, Gallina P, Sergi LS, Merella S, Bulfone A, Doglioni C, von Kalle C, Kim YJ, Schmidt M, Tonon G, Naldini L, Montini E. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013, 10:155-161. 10.1038/nmeth.2331, 3589714, 23314173.
5. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005, 436:272-276. 10.1038/nature03681, 16015333.
6. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, Asnafi V, MacIntyre E, Dal Cortivo L, Radford I, Brousse N, Sigaux F, Moshous D, Hauer J, Borkhardt A, Belohradsky BH, Wintergerst U, Velez MC, Leiva L, Sorensen R, Wulffraat N, Blanche S, Bushman FD, Fischer A, Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142. 10.1172/JCI35700, 2496963, 18688285.
7. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419. 10.1126/science.1088547, 14564000.
8. Visakorpi T. The molecular genetics of prostate cancer. Urology 2003, 62:3-10.
9. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003, 349:366-381. 10.1056/NEJMra021562, 12878745.
10. Porkka KP, Visakorpi T. Molecular mechanisms of prostate cancer. Eur Urol 2004, 45:683-691. 10.1016/j.eururo.2004.01.012, 15149739.
11. Lu S, Tsai SY, Tsai MJ. Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology 1999, 140:5054-5059.
12. Gulley J, Figg WD, Dahut WL. Treatment options for androgen-independent prostate cancer. Clin Adv Hematol Oncol 2003, 1:49-57.
13. Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F. Novel strategies in the treatment of castration-resistant prostate cancer (Review). Int J Oncol 2012, 40:1313-1320.
14. Pousette A, Carlstrom K, Henriksson P, Grande M, Stege R. Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Prostate 1997, 31:198-203. 10.1002/(SICI)1097-0045(19970515)31:3<198::AID-PROS9>3.0.CO;2-H, 9167773.
15. Iguchi K, Ishii K, Nakano T, Otsuka T, Usui S, Sugimura Y, Hirano K. Isolation and characterization of LNCaP sublines differing in hormone sensitivity. J Androl 2007, 28:670-678. 10.2164/jandrol.107.002675, 17409465.
16. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983, 43:1809-1818.
17. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997, 57:1584-1589.
18. Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res 2009, 69:4388-4397. 10.1158/0008-5472.CAN-08-3901, 2710962, 19401450.
19. Heim D, Cornils K, Schulze K, Fehse B, Lohse AW, Brummendorf TH, Wege H. Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis. Oncogene 2014, doi:10.1038/onc.2013.551.
20. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C, Di Serio C, von Kalle C, Naldini L. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009, 119:964-975. 10.1172/JCI37630, 2662564, 19307726.
21. Trobridge GD, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R, Russell DW. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci U S A 2006, 103:1498-1503. 10.1073/pnas.0510046103, 1360565, 16428288.
22. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. Jama 2005, 294:238-244. 10.1001/jama.294.2.238, 16014598.
23. Wang X, An Z, Geller J, Hoffman RM. High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP. Prostate 1999, 39:182-186. 10.1002/(SICI)1097-0045(19990515)39:3<182::AID-PROS6>3.0.CO;2-B, 10334107.
24. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005, 174:6477-6489. 10.4049/jimmunol.174.10.6477, 15879151.
25. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 10.1016/S1476-5586(04)80047-2, 1635162, 15068665.
26. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM, Bubley GJ, Li V, Rubin MA, Libermann TA, Sanda MG. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 2009, 15:5794-5802. 10.1158/1078-0432.CCR-09-0911, 19737960.
27. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243. 10.1038/nature11125, 3396711, 22722839.
28. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004, 164:217-227. 10.1016/S0002-9440(10)63112-4, 1602218, 14695335.
29. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004, 101:811-816. 10.1073/pnas.0304146101, 321763, 14711987.
30. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006, 66:4011-4019. 10.1158/0008-5472.CAN-05-3055, 16618720.
31. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M. Gene expression analysis of prostate cancers. Mol Carcinog 2002, 33:25-35. 10.1002/mc.10018, 11807955.
32. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001, 61:5692-5696.
33. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203-209. 10.1016/S1535-6108(02)00030-2, 12086878.
34. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22. 10.1016/j.ccr.2010.05.026, 3198787, 20579941.
35. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39:41-51. 10.1038/ng1935, 17173048.
36. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003, 63:3877-3882.
37. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8:393-406. 10.1016/j.ccr.2005.10.001, 16286247.
38. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008, 68:927-936. 10.1158/0008-5472.CAN-07-2608, 18245496.
39. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001, 61:5974-5978.
40. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005, 65:3081-3091.
41. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009, 458:97-101. 10.1038/nature07638, 2725402, 19136943.
42. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, Lonigro RJ, Schroth G, Kumar-Sinha C, Chinnaiyan AM. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A 2009, 106:12353-12358. 10.1073/pnas.0904720106, 2708976, 19592507.
43. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007, 67:8504-8510. 10.1158/0008-5472.CAN-07-0673, 17875689.
44. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 2004, 13:1303-1313. 10.1093/hmg/ddh155, 15138198.
45. Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R, Kalyana-Sundaram S, Michailidis G, Nesvizhskii AI, Omenn GS, Chinnaiyan AM, Sreekumar A. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 2010, 9:298-312. 10.1074/mcp.M900159-MCP200, 2830841, 19955085.
46. Tomlins SA, Rubin MA, Chinnaiyan AM. Integrative biology of prostate cancer progression. Annu Rev Pathol 2006, 1:243-271. 10.1146/annurev.pathol.1.110304.100047, 18039115.
47. Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran T, Yu J, Varambally S, Li Y, Omenn GS, Chinnaiyan AM, Nesvizhskii AI. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One 2009, 4:e7075. 10.1371/journal.pone.0007075, 2740864, 19763266.
48. Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, Meeker AK, Netto G, De Marzo AM, Nelson WG, Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010, 42:668-675. 10.1038/ng.613, 3157086, 20601956.
49. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230. 10.1126/science.1178124, 2935583, 19933109.
50. Armisen R, Marcelain K, Simon F, Tapia JC, Toro J, Quest AF, Stutzin A. TRPM4 enhances cell proliferation through up-regulation of the beta-catenin signaling pathway. J Cell Physiol 2011, 226:103-109. 10.1002/jcp.22310, 20625999.
51. Fraser SP, Pardo LA. Ion channels: functional expression and therapeutic potential in cancer. Colloquium on Ion Channels and Cancer. EMBO Rep 2008, 9:512-515. 10.1038/embor.2008.75, 2427390, 18451877.
52. Prevarskaya N, Flourakis M, Bidaux G, Thebault S, Skryma R. Differential role of TRP channels in prostate cancer. Biochem Soc Trans 2007, 35:133-135. 10.1042/BST0350133, 17233619.
53. Roginski RS, Mohan Raj BK, Birditt B, Rowen L. The human GRINL1A gene defines a complex transcription unit, an unusual form of gene organization in eukaryotes. Genomics 2004, 84:265-276. 10.1016/j.ygeno.2004.04.004, 15233991.
54. Le TP, Sun M, Luo X, Kraus WL, Greene GL. Mapping ERbeta genomic binding sites reveals unique genomic features and identifies EBF1 as an ERbeta interactor. PLoS One 2013, 8:e71355. 10.1371/journal.pone.0071355, 3738513, 23951143.
55. Hartman J, Strom A, Gustafsson JA. Current concepts and significance of estrogen receptor beta in prostate cancer. Steroids 2012, 77:1262-1266. 10.1016/j.steroids.2012.07.002, 22824289.
56. Aung CS, Hill MM, Bastiani M, Parton RG, Parat MO. PTRF-cavin-1 expression decreases the migration of PC3 prostate cancer cells: role of matrix metalloprotease 9. Eur J Cell Biol 2011, 90:136-142. 10.1016/j.ejcb.2010.06.004, 20732728.
57. Gould ML, Williams G, Nicholson HD. Changes in caveolae, caveolin, and polymerase 1 and transcript release factor (PTRF) expression in prostate cancer progression. Prostate 2010, 70:1609-1621. 10.1002/pros.21195, 20564315.
58. Nassar ZD, Moon H, Duong T, Neo L, Hill MM, Francois M, Patron RG, Parat MO. PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis. Oncotarget 2013, 4:1844-1855. 3858569, 24123650.
59. Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Le Cao KA, Winterford C, Coward JI, Ling MT, Craik DJ, Parton RG, Russell PJ, Hill MM, the Australian Prostate Cancer BioResource PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene 2013, doi:10.1038/onc.2013.315, the Australian Prostate Cancer BioResource.
60. Buchet-Poyau K, Courchet J, Le Hir H, Seraphin B, Scoazec JY, Duret L, Domon-Dell C, Freund JN, Billaud M. Identification and characterization of human Mex-3 proteins, a novel family of evolutionarily conserved RNA-binding proteins differentially localized to processing bodies. Nucleic Acids Res 2007, 35:1289-1300. 10.1093/nar/gkm016, 1851655, 17267406.
61. Mougeot JL, Bahrani-Mougeot FK, Lockhart PB, Brennan MT. Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 112:446-452. 10.1016/j.tripleo.2011.05.009, 21862359.
62. Wang ZG, Ackerman SH. The assembly factor Atp11p binds to the beta-subunit of the mitochondrial F(1)-ATPase. J Biol Chem 2000, 275:5767-5772. 10.1074/jbc.275.8.5767, 10681564.
63. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, Garcia-Huerta P, Sanchez-Arago M, Cuezva JM. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H + -ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 2010, 285:25308-25313. 10.1074/jbc.M110.146480, 2919093, 20538613.
64. Trobridge GD, Wu RA, Hansen M, Ironside C, Watts KL, Olsen P, Beard BC, Kiem HP. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol Ther 2010, 18:725-733. 10.1038/mt.2009.282, 2862537, 19997089.
65. Kent WJ. BLAT-the BLAST-like alignment tool. Genome Res 2002, 12:656-664. 10.1101/gr.229202. Article published online before March 2002, 187518, 11932250.
66. Chapman DG. The Estimation of Biological Populations. Ann Math Stat 1954, 25:1-14.
67. Krebs CJ. From Chapter 2 Estimating Abundance: Mark-Recapture Techniques. Ecological Methodology 1998, 35-41. Menlo Park, California: Addison Wesley Longman, Inc., 2.